Dr. Reddy's Laboratories, Aurigene Pharmaceutical Services, And Kainomyx Sign Non-Binding MoU For Joint Development Of Affordable Anti-Malarial Drug
Dr. Reddy's Laboratories, Aurigene Pharmaceutical Services, And Kainomyx Sign Non-Binding MoU For Joint Development Of Affordable Anti-Malarial Drug
- Malaria is a life-threatening public health issue, particularly in low- and middle-income countries. There is a need for an effective, affordable, and accessible preventive and/or treatment medication. This potential partnership is a step towards this cause
- This potential partnership aims to bring together Kainomyx's expertise in novel drug discovery, Aurigene's capability to conduct integrated drug discovery and development, and Dr. Reddy's ability to commercialize products in low and middle-income countries, in addition to the US and Europe
- It is a testament to the commitment of involved parties towards promoting global public health and Dr. Reddy's goal of reaching 1.5 billion patients by 2030
- 瘧疾是一項威脅公共健康的問題，特別是在低收入和中等收入國家。需要一種有效、實惠和可訪問的預防和/或治療藥物。這種潛在的夥伴關係是邁向這個目標的一步。
- 這種潛在的夥伴關係旨在將Kainomyx的新藥發現專業知識，Aurigene進行一體化藥物發現和開發的能力以及Dr. Reddy在低收入和中等收入國家，以及美國和歐洲生產產品的能力結合起來。
- 它證明了各方致力於促進全球公共衛生和Dr. Reddy在2030年前達到15億患者的目標的承諾。
Dr. Reddy's Laboratories Ltd. ((BSE: 500124, NSE: DRREDDY, NYSE:RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as "Dr. Reddy's")), and its CRDMO arm Aurigene Pharmaceutical Services Limited (Aurigene), today announced that they have signed a non-binding Memorandum of Understanding (MoU) with Kainomyx, Inc., a US-based company with a proprietary platform that helps target cytoskeletal proteins of parasites, a novel mechanism of action, for the development and commercialization of affordable anti-malarial drug in the U.S., Europe, and in low and middle-income countries. The MoU remains subject to signing of a definitive agreement.
Dr. Reddy's Laboratories Ltd. ((BSE: 500124，NSE: DRREDDY，NYSE:RDY，NSEIFSC: DRREDDY，及其附屬公司合稱"Dr. Reddy's")和其CRDMO子公司Aurigene Pharmaceutical Services Limited (Aurigene)今天宣佈，他們已經與Kainomyx簽署了一份非約束性諒解備忘錄(MoU)，Kainomyx是一家總部位於美國的具有專有平台的公司，該平台有助於針對寄生蟲細胞骨架蛋白的靶向作用，這是一種新穎的作用機制，用於開發和生產價格實惠的抗瘧疾藥物，在美國，歐洲以及低收入和中等收入國家。諒解備忘錄仍待簽署最終協議。
譯文內容由第三人軟體翻譯。